ixazomib + cyclophosphamide + ascorbic acid

**ixazomib + cyclophosphamide + ascorbic acid** is a combination regimen presumed to be used in the treatment of multiple myeloma or related plasma cell disorders. Each component contributes a distinct mechanism of action: - **Ixazomib** is an oral small molecule proteasome inhibitor that blocks the chymotrypsin-like activity of the 20S proteasome, leading to apoptosis in malignant plasma cells. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, resulting in inhibition of DNA replication and cell death in rapidly dividing cells. - **Ascorbic acid (Vitamin C)** at pharmacological doses acts as a pro-oxidant in the context of malignancy, facilitating the generation of reactive oxygen species and contributing to cancer cell apoptosis. This combination's mechanism is based on combining DNA damage (cyclophosphamide), proteasome inhibition (ixazomib), and oxidative stress (ascorbic acid) for potential additive or synergistic antimyeloma effects. There is evidence for similar combinations (with bortezomib or carfilzomib replacing ixazomib) enhanced by ascorbic acid in relapsed/refractory multiple myeloma, although direct combination data with all three agents is very limited and likely experimental[4][5][7]. Primary indication is presumed to be **multiple myeloma**.